Search results
Results from the WOW.Com Content Network
The study found a 39% lower HIV infection rate in women using 1% tenofovir gel compared with women using a placebo gel. In addition, tenofovir gel was shown to be safe as tested. [ 21 ] The results of the CAPRISA 004 trial provide statistically significant evidence that ARVs, topically applied to the vaginal mucosa, can offer protection against ...
Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Unsourced material may be challenged and removed. Find sources: "List of antiretroviral fixed-dose combinations" – news · newspapers · books · scholar · JSTOR ( January 2021 ) ( Learn how and when to remove this ...
Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.
The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies. The abbreviations in the column Type are as follows: mab: whole monoclonal antibody; Fab: fragment, antigen-binding (one arm)
Stavudine is used in the treatment of HIV-1 infection, but is not a cure.It is not normally recommended as initial treatment. [6] Stavudine can also reduce the risk of developing HIV-1 infection after coming into contact with the virus either at work (e.g., needlestick) or through exposure to infected blood or other bodily fluids. [7]
For premium support please call: 800-290-4726 more ways to reach us
Efavirenz is not effective against HIV-2, as the pocket of the HIV-2 reverse transcriptase has a different structure, which confers intrinsic resistance to the NNRTI class. [ 20 ] As most NNRTIs bind within the same pocket, viral strains which are resistant to efavirenz are usually also resistant to the other NNRTIs, nevirapine and delavirdine .
The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company. [1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi. [ 2 ]